Ibrutinib's off-target mechanism: cause for dose optimization.

Area of Science:

• Oncology
• Pharmacology

Background:

• Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor used for B-cell malignancies and chronic graft-versus-host disease (cGVHD).
• Cardiac adverse events, particularly atrial fibrillation, are significant side effects of ibrutinib treatment, often leading to dose interruption or discontinuation.
• Atrial fibrillation is linked to reduced progression-free survival in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib.

Purpose of the Study:

• To explore the mechanism of ibrutinib-induced atrial fibrillation.
• To evaluate the potential for alternative dosing strategies to mitigate cardiac risks.
• To investigate if lower ibrutinib doses can maintain efficacy in CLL.

Main Methods:

• Review of recent findings on ibrutinib's mechanism of action.
• Analysis of *in vitro* and *in vivo* data regarding ibrutinib's biological activity at reduced doses.
• Discussion of clinical implications for dosing adjustments.

Main Results:

• Xiao et al. identified off-target CSK inhibition as a likely cause of ibrutinib-mediated atrial fibrillation.
• Promising evidence suggests maintained biological activity of ibrutinib in CLL at lower doses.
• The mechanism provides a rationale for investigating alternative dosing schedules.

Conclusions:

• Understanding the off-target effects of ibrutinib, such as CSK inhibition, is crucial for managing cardiac risks.
• Alternative dosing strategies for ibrutinib may reduce the incidence of atrial fibrillation.
• Further investigation into optimal ibrutinib dosing is warranted to balance efficacy and safety.